Close Menu

NEW YORK (360Dx) – Cancer detection firm Oncimmune today announced the first distribution deals for its autoantibody-based lung cancer test.

Under the terms of the deals, Israel-based Best Medical Opinion and South Korea-based Dow Biomedica/Biodiscovery will distribute Oncimmune's EarlyCDTLung cancer test in those countries. The agreements allow for the sale of the test as a central laboratory test while Oncimmune finishes the CE marking of a kit form of EarlyCDTLung.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.

Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.

New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.